Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 7Lymphoid 7Plasma cell 2Classical hematology 2Sarcoma 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 162Nivolumab 135Ipilimumab 80Cyclophosphamide 47Specimen Handling 43Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 22fludarabine phosphate 20dabrafenib 20atezolizumab 19Radiotherapy 19Opdualag 19CTLA-4 Antigen 19aldesleukin 18Radiosurgery 18encorafenib 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lifileucel 11lenvatinib 11Paclitaxel 11Bevacizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cyclosporins × Dermatologic × 1 year × Clear all
NCT00133887 2025-12-26

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

Hospices Civils de Lyon

Phase 3 Completed
77 enrolled
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡